Mostal

Pyrus Malus (apple) Fruit Extract

Pella Pharmaceuticals Co. Ltd
Human Otc Drug
NDC 82160-306

Mostal also known as Pyrus Malus (apple) Fruit Extract is a human otc drug labeled by 'Pella Pharmaceuticals Co. Ltd'. National Drug Code (NDC) number for Mostal is 82160-306. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Mostal drug includes Apple - 500 mg/50mL . The currest status of Mostal drug is Active.

Drug Information:

Drug NDC:	82160-306
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Mostal
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Pyrus Malus (apple) Fruit Extract
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Pella Pharmaceuticals Co. Ltd
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	APPLE - 500 mg/50mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	20 Jan, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	07 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date:	31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	Pella Pharmaceuticals Co. Ltd
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:	Yes
Whether or not the drug has been repackaged for distribution.
UPC:	6253344200306
UPC stands for Universal Product Code.
NUI:	N0000185371 N0000175629 M0000728 M0006342 N0000185015
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:	B423VGH5S9
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:	Non-Standardized Food Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:	Increased Histamine Release [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:	Allergens [CS] Dietary Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:	Allergens [CS] Dietary Proteins [CS] Fruit Proteins [EXT] Increased Histamine Release [PE] Non-Standardized Food Allergenic Extract [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
82160-306-01	1 BOTTLE, GLASS in 1 CARTON (82160-306-01) / 50 mL in 1 BOTTLE, GLASS	20 Jan, 2011	N/A	No
82160-306-02	3 BOTTLE, GLASS in 1 CARTON (82160-306-02) / 50 mL in 1 BOTTLE, GLASS	20 Jan, 2011	N/A	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Mostal

Pyrus Malus (apple) Fruit Extract

Solution
Pella Pharmaceuticals Co. Ltd
NDC: 82160-306

Purpose:

Purpose hair growth enhancer

Product Elements:

Mostal pyrus malus (apple) fruit extract anhydrous citric acid propylene glycol apple apple alcohol water sodium citrate

Indications and Usage:

Indications mostal Â® solution is recommended for men and women to stop hair fall; improves hair growth and increases its density.

Warnings:

Warnings for external use only avoid eye contact for accidental ingestion; seek professional attention, some redness and irritation is normal initially, if it persists discontinue use avoid contact with fabrics until it dries out

Dosage and Administration:

Dosage and administration spraying the solution on the scalp, the solution gently massaged into the scalp for 10 to 20 seconds, twice daily. the increase in frequency of use, increases efficiency.

Contraindications:

Contraindications hypersensitivity to any of the components.

Adverse Reactions:

Side effects mostal Â® solution has no known side effect, the use of it is without risk.

Description:

Properties mostal Â® solution that helps to stop hair fall; improves hair growth and increases its density.

How Supplied:

Forms and presentation topical solution: bottle of 50 ml.

Package Label Principal Display Panel:

Label label

Secondary package secondary package

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.